Functionalized quinolizininium-based fluorescent reagents for modification of cysteine-containing peptides and proteins

Karen Ka-Yan Kung,a,b Cai-fung Xu,a Wa-Yi O,a,b Qiong Yu,a Sai-Fung Chung,c Suet-Ying Tam,c Yun-Chung Leung,c and Man-Kin Wong*a,b

a The Hong Kong Polytechnic University Shenzhen Research Institute, Shenzhen, 518057, China.
b State Key Laboratory of Chemical Biology and Drug Discovery, and Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hung Hom, Hong Kong, China.
c Henry Cheng Research Laboratory for Drug Development and Lo Ka Chung Centre for Natural Anti-Cancer Drug Development, The Hong Kong Polytechnic University, Hung Hom, Hong Kong, China.

E-mail: mankin.wong@polyu.edu.hk; thomas.yun-chung.leung@polyu.edu.hk

Supporting Information
**Table of Content**

| Section                                                                 | Page |
|------------------------------------------------------------------------|------|
| Literature References                                                  | S3   |
| General Procedures                                                     | S4   |
| ESI-MS Analysis of Peptide Modification                                | S5   |
| ESI-MS Analysis of Protein Modification                               | S5   |
| Calculation of Peptide Conversion                                      | S5   |
| Calculation of Protein Conversion                                      | S8   |
| Synthesis of Compounds                                                 | S13  |
| Photophysical Properties of Compounds                                  | S17  |
| Procedure of Peptide Modification                                      | S18  |
| Procedure of Protein Modification                                      | S18  |
| Procedure for SDS-PAGE Analysis                                        | S18  |
| Procedure for Trypsin Digestion                                        | S18  |
| Procedure for Site-Directed Mutagenesis of BCArg                       | S19  |
| Mutated BCArg Peptide Sequence                                         | S21  |
| Enzyme Activity                                                        | S21  |
| Inhibition of *in vitro* Cancer Cell Proliferation                     | S21  |
| $^1$H and $^{13}$C NMR Spectra                                         | S22  |
| LC-MS and LC-MS/MS of Peptides                                        | S36  |
| LC-MS and LC-MS/MS of Proteins                                        | S64  |
| UV/Visible Absorption Spectra of Quinolizinium Compounds               | S82  |
| Supplementary References                                               | S90  |
| Literature References | AuPPh₃Cl |
|-----------------------|---------|
| K. Nunokawa, S. Onaka, T. Tatematsu, M. Ito and J. Sakai, *Inorg. Chim. Acta*, 2001, 322, 56-64. |
| J.-R. Deng, W.-C. Chan, N. Chun-Him Lai, B. Yang, C.-S. Tsang, B. Chi-Bun Ko, S. Lai-Fung Chan, M.-K. Wong, *Chem. Sci.*, 2017, 8, 7537–7544. |
| J. Tang, L.-M. Wang, D. Mao, W.-B. Wang, L. Zhang, S.-Y. Wu, Y.-S. Xie, *Tetrahedron*, 2011, 67, 8465–8469. |
| (1) F. Zhou and T. G. Driver, *Org. Lett.*, 2014, 16, 2916–2919. |
| (2) Yan, L., Che, X., Bai, X. *et al*. *Mol. Divers.*, 2012, 16, 489–501. |
| (1) H.-Y. Li, J. Horn, A. Campbell, D. House, A. Nelson and S. P. Marsden, *Chem. Commun.*, 2014, 50, 10222–10224. |
| (2) Yan, L., Che, X., Bai, X. *et al*. *Mol. Divers.*, 2012, 16, 489–501. |
| J.-R. Deng, W.-C. Chan, N. Chun-Him Lai, B. Yang, C.-S. Tsang, B. Chi-Bun Ko, S. Lai-Fung Chan, M.-K. Wong, *Chem. Sci.*, 2017, 8, 7537–7544. |
**General Procedures**

All reagents were commercially available and used without further purification. All peptides (>98% purity) were directly purchased from GL Biochem (Shanghai) Ltd. BSA, HSA and lysozyme were purchased from Sigma Aldrich and used without further purification. Milli-Q® water used as reaction solvent in peptide and protein modification, as well as LC-MS analysis, was deionised using a Milli-Q® Gradient A10 system (Millipore, Billerica, USA). Flash column chromatography was performed using silica gel 60 (230-400 mesh ASTM) with ethyl acetate/n-hexane or methanol/dichloromethane as eluent. All NMR spectra were recorded on a Bruker DPX-400 spectrometer. All chemical shifts are quoted on the scale in ppm using TMS or residual solvent as the internal standard. Coupling constants (\(J\)) are reported in Hertz (Hz) with the following splitting abbreviations: \(s =\) singlet, \(br\ s =\) broad singlet, \(d =\) doublet, \(dd =\) double doublet, \(t =\) triplet and \(m =\) multiplet. All mass spectra were obtained on an ESI source of Agilent 6540 Ultra High Definition (UHD) Accurate-Mass Q-TOF LC/MS systems in the positive and negative ion modes.

All the photochemical experiments were performed custom-made “lightbox” with 4 reaction vessels surrounded by 16 blue LED light bulbs. The temperature was maintained by a fan attached to “lightbox”. A voltage transformer was connected with the blue LEDs and employed to monitor the power of the light source \(P = U \times I = 14.3 \, V \times 2.3 \, A = 32.9 \, W\). 4 reactions were performed in the “lightbox” every time for measurement of the reaction yields. The emission spectra of the blue LEDs revealed a maximum emission wavelength of the light source at \(\lambda_{\text{max}} = 468\, \text{nm}\) (Figure S1).\(^1\)

![Emission spectrum of the Blue LEDs light source.](https://example.com/spectrum.png)

**Figure S1.** Emission spectrum of the Blue LEDs light source.
ESI-MS Analysis of Peptide Modification

LC-MS analyses for peptide identification were performed by using an Agilent 6540 UHD Accurate-Mass Q-TOF LC/MS system equipped with an ion spray source and an Agilent 1290 Infinity LC, using an Agilent ZORBAX RRHD SB300-C18 (1.8 μm, 2.1 x 100 mm) column. 3 μL of the sample was injected with a flow rate of the flow rate was 0.2 mL/min. Mobile phase A was made of Milli-Q® water containing 0.1% formic acid. Mobile phase B was made of HPLC grade acetonitrile containing 0.1% formic acid. The initial conditions for separation were 5% B for 3 min, followed by a linear gradient to 95% B by 22 min. The composition was maintained for 1 min, followed by a linear gradient to 5% B by 1 min. The composition was maintained for 4 min. Operating conditions optimized for the detection of the reaction mixture were the following: Gas temperature: 380 °C, Drying gas: 8 L/min, Nebulizer: 35 psig, Sheath gas temperature: 270 °C, Sheath gas flow: 11 L/min, VCap: 3500 V, Nozzle voltage: 1000 V.

ESI-MS Analysis of Protein Modification

LC-MS analyses for protein identification were performed by using an Agilent 6540 UHD Accurate-Mass Q-TOF LC/MS system equipped with an ion spray source and an Agilent 1290 Infinity LC, using an Agilent ZORBAX RRHD SB300-C3 (1.8 μm, 2.1 x 100 mm) column. 3 μL of the sample was injected with a flow rate of the flow rate was 0.3 mL/min. Mobile phase A was made of Milli-Q® water containing 0.1% formic acid. Mobile phase B was made of HPLC-grade acetonitrile containing 0.1% formic acid. The initial conditions for separation were 5% B for 2 min, followed by a linear gradient to 95% B by 12 min. The composition was maintained for 1 min, followed by a linear gradient to 5% B by 0.1 min. The composition was maintained for 1.9 min. Operating conditions optimized for the detection of the reaction mixture were the followings: Gas temperature: 320 °C, Drying gas: 8 L/min, Nebulizer: 45 psig, Sheath gas temperature: 380 °C, Sheath gas flow: 11 L/min, VCap: 3500 V, Nozzle voltage: 1000 V.

Calculation of Peptide Conversion

The crude reaction mixture of unmodified peptide (starting) and modified peptide (product) was subjected to LC-MS analysis with elution time of 31 min. After data processing by Agilent MassHunter software, peptide conversion at different time intervals was determined by measuring the peak areas of starting and product in the total ion chromatogram (TIC) and extracted ion chromatogram (XIC) as follows:
Equation 1

\[
\text{Peptide Conversion (\%)} = \left( \frac{\text{Peak Area of Product}}{\text{Peak Areas of Starting and Product}} \right) \times 100\%
\]

1a-modified STSSSCNLSK was used as an example of the calculation of the peptide conversion. After integrating the peak areas of STSSSCNLSK, 1a-modified STSSSCNLSK and dimerized STSSSCNLSK, 1a-modified STSSSCNLSK and dimerized STSSSCNLSK were afforded in 89% and 6% conversions, respectively (Figure S2). The above method for calculating the peptide conversion has been used in all the bioconjugation reactions of peptides.

**Figure S2.** Modification of peptide STSSSCNLSK with quinolizinium 1a in 50 mM pH 7.4 PBS buffer/DMSO (90:10) for 6 h (Top). Total ion chromatogram for crude reaction mixture of 1a-modified STSSSCNLSK (Bottom).
Table S1. Expected and observed masses of the modified peptides.

| Modified Peptide   | Expected Mass [M]^+ | Observed Mass [M]^+ |
|--------------------|---------------------|---------------------|
| 1a-modified STSSSCNLCK | 1442.6117          | 1442.60             |
| 1b-modified STSSSCNLCK | 1518.6430          | 1518.66             |
| 1c-modified STSSSCNLCK | 1472.6223          | 1472.62             |
| 1d-modified STSSSCNLCK | 1457.6223          | 1457.62             |
| 1e-modified STSSSCNLCK | 1533.6539          | 1533.66             |
| 1f-modified STSSSCNLCK | 1487.6332          | 1487.64             |
| 1g-modified STSSSCNLCK | 1525.6100          | 1525.61             |
| 1h-modified STSSSCNLCK | 1457.6226          | 1457.62             |
| 1a-modified AYEMWCFHQR   | 1799.7318          | 1799.74             |
| 1b-modified AYEMWCFHQR   | 1875.7631          | 1875.77             |
| 1c-modified AYEMWCFHQR   | 1829.7423          | 1829.75             |
| 1d-modified AYEMWCFHQR   | 1814.7427          | 1814.74             |
| 1e-modified AYEMWCFHQR   | 1890.7740          | 1890.78             |
| 1f-modified AYEMWCFHQR   | 1844.7532          | 1844.75             |
| 1g-modified AYEMWCFHQR   | 1882.7300          | 1882.73             |
| 1h-modified AYEMWCFHQR   | 1814.7427          | 1814.74             |
| 1a-modified AYEMWCFHQK    | 1771.7256          | 1771.71             |
| 1d-modified AYEMWCFHQK    | 1786.7441          | 1786.71             |
| 1h-modified AYEMWCFHQK    | 1786.7441          | 1786.71             |
| 1a-modified CSKFR         | 1069.4784          | 1069.48             |
| 1d-modified CSKFR         | 1084.4893          | 1084.49             |
| 1h-modified CSKFR         | 1084.4893          | 1084.49             |
| 1a-modified KSTFC         | 1014.4250          | 1014.42             |
| 1d-modified KSTFC         | 1029.4359          | 1029.43             |
| 1h-modified KSTFC         | 1029.4359          | 1029.43             |
| 1a-modified ASCGTN        | 981.3631           | 981.35              |
| 1d-modified ASCGTN        | 996.3740           | 996.37              |
| 1h-modified ASCGTN        | 996.3740           | 996.37              |
Calculation of Protein Conversion

The crude reaction mixture of unmodified protein (starting) and modified protein (product) was subjected to LC-MS analysis with an elution time of 15 min. After data processing by Agilent MassHunter software, protein conversion at different time intervals was determined by measuring the peak areas of starting and product in the total ion chromatograms and extracted ion chromatograms as follows:

**Equation 2**

\[
\text{Protein Conversion (\%) = } \left( \frac{\text{Peak Area of Product}}{\text{Peak Areas of Starting and Product}} \right) \times 100\%
\]

1a-modified BSA was used as an example of the calculation of the protein conversion. After integrating the peak areas of BSA and 1a-modified BSA, the protein conversion was found to be 74% for 1a-modified BSA (1 equiv. of 1a used) in 50 mM PBS (pH 7.4)/DMSO (95:5) (Figure S3). The above method for calculating the protein conversion has been used for all the bioconjugation reactions of proteins.

**Figure S3.** Modification of BSA with quinolizininium 1a (1 equiv. of 1a used) in 50 mM PBS buffer (pH 7.4) /DMSO (95:5) for 16 h (Top). Total ion chromatogram for crude reaction mixture of 1a-modified BSA (Bottom).
The protein conversion measurement in the present bioconjugation by LC-MS analysis was investigated. Prior to LC-MS analysis, total protein concentrations of unmodified BSA and 1a-modified BSA (1 equiv. of 1a used) were found to be 6.124 mg/mL and 6.688 mg/mL BSA, respectively, by A280 assay using Thermo Scientific NanoDrop One. UV spectrum of 1a-modified BSA was shown to be similar to that of BSA (Figure S4). Then, 0%, 25%, 50%, 75% and 100% of 1a-modified BSA were prepared by pipetting different concentration ratios of BSA and 1a-modified BSA and then subjected to LC-MS analysis. The protein conversions of 0%, 25%, 50%, 75% and 100% of 1a-modified BSA were found to be 0%, 31%, 39%, 59% and 74% as determined by the extracted ion chromatograms (i.e. m/z 1385.00 for BSA; m/z 1393.94 for 1a-modified BSA) using Equation 2. The corresponding deconvolution mass spectra were shown in Figure S5. A graph of conversion (%) by the extracted ion chromatogram (XIC) versus % of 1a-modified BSA by A280 assay was plotted and showed good linearity with \( R^2 = 0.975 \) (Figure S6). Thus, Equation 2 is adopted for the determination of protein conversion.

![Figure S4. UV spectra of BSA and 1a-modified BSA (1 equiv. of 1a used) in Thermo Scientific NanoDrop One.](image-url)
Figure S5. Deconvolution mass spectra of (a) 100%, (b) 75%, (c) 50%, (d) 25% and (e) 0% of 1a-modified BSA (1 equiv. of 1a used).
Figure S6. A graph of conversion (%) by XIC versus % of 1a-modified BSA (1 equiv. of 1a used) by A280 assay.

\[ y = 0.7054x + 4.3631 \]
\[ R^2 = 0.975 \]
Table S2. Expected and observed masses of the modified proteins.

| Modified Protein                  | Expected Mass [M]^+ | Observed Mass [M]^+ |
|-----------------------------------|---------------------|---------------------|
| 1a-modified BSA                   | 66861               | 66861               |
| 1b-modified BSA                   | 66952               | 66952               |
| 1d-modified BSA                   | 66876               | 66876               |
| 1e-modified BSA                   | 66952               | 66952               |
| 1h-modified BSA                   | 66876               | 66876               |
| 1a-modified HSA                   | 66871               | 66870               |
| 1b-modified HSA                   | 66947               | 66947               |
| 1d-modified HSA                   | 66886               | 66883               |
| 1e-modified HSA                   | 66962               | 66961               |
| 1h-modified HSA                   | 66886               | 66884               |
| 1a-modified BCArg mutant          | 32878               | 32878               |
| 1b-modified BCArg mutant          | 32954               | 32954               |
| 1d-modified BCArg mutant          | 32893               | 32892               |
| 1e-modified BCArg mutant          | 32969               | 32969               |
| 1h-modified BCArg mutant          | 32893               | 32893               |
**Synthesis of Compound 2a**

A solution of 4-[(trimethylsilyl)ethynyl]benzaldehyde (500 mg, 3 mmol) and ethynlmagnesium bromide solution (21 mL, 10.5 mmol) in 20 mL of anhydrous THF was stirred at 0 °C for 1 h. 5 mL of H₂O was carefully added to the reaction mixture to quench the reaction. After evaporation of THF, the resulting solution was acidified with 10% H₂SO₄. The reaction mixture was extracted with EtOAc (3 × 20 mL). The combined organic layer was dried over anhydrous MgSO₄, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (EtOAc/n-hexane) to give product 4.

A solution of 4 (98 mg, 0.46 mmol), chromium (VI) oxide (92 mg, 0.92 mmol) and CH₃COOH (276 mg, 4.6 mmol) in 5 mL of acetone was stirred at 0 °C for 3 h. After the reaction, the residue was filtered by Celite, evaporated and then purified by flash column chromatography in ethyl acetate/n-hexane to give product 2a.

![2a](image)

White solid, 43% yield. ¹H NMR (400 MHz, CDCl₃) δ 8.07 (d, J = 8.3 Hz, 2H), 7.55 (d, J = 8.3 Hz, 2H), 3.47 (s, 1H), 0.26 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 176.65, 135.64, 132.33, 129.65, 104.04, 99.67, 81.44, 80.34, 77.47, 77.26, 77.05, 0.19, 0.00, -0.19. HRMS (ESI) m/z calcd. for C₁₄H₁₃OSi⁺ [M + H]⁺ 227.0887, found 227.0885.
Synthesis of Compound 2b

Under nitrogen atmosphere, 4-(2-trimethylsilylethynyl)aniline (100 mg, 0.34 mmol) was dissolved in anhydrous dichloromethane (20 mL) and then cooled down to 0 °C by placing the reaction flask into an ice-water bath. Propiolic acid (48 mg, 0.68 mmol), N,N'-dicyclohexylcarbodiimide (DCC) (140 mg, 0.68 mmol) and 4-di(methylamino)pyridine (DMAP) (1 mg, a catalytic amount) were added to the reaction mixture. The reaction mixture was stirred for 16 h. After evaporation of the solvent, and removing the white participate by filtration, the residue was purified by flash column chromatography in ethyl acetate/n-hexane to afford product 2b.

\[
\text{HN-SiMe}_3
\]

White solid, 70% yield. \(^1\text{H NMR}\) (400 MHz, CDCl\(_3\)) \(\delta\) 7.82 (s, 1H), 7.48 (d, \(J = 8.7\) Hz, 2H), 7.42 (d, \(J = 8.7\) Hz, 2H), 2.94 (s, 1H), 0.24 (s, 9H). \(^{13}\text{C NMR}\) (100 MHz, CDCl\(_3\)) \(\delta\) 149.71, 137.21, 132.98, 119.90, 119.62, 104.60, 94.54, 77.56, 74.65, 0.08. \(\text{HRMS (ESI) m/z}\) calcd. for \(\text{C}_{14}\text{H}_{16}\text{NOSi}^+ [M + H]^+ 242.0996\), found 242.0993.
Synthesis of Aryl Diazonium 3b.

A mixture of 2-nitrobenzaldehyde (10 mmol, 1 equiv.), aniline (12 mmol, 1.2 equiv.), phenylacetylene (12 mmol, 1.2 equiv.), KAuCl₄ (5 mol%) and CuBr (30 mol%) in 20 mL of methanol were heated in a 50 mL round bottom flask at 40 °C under nitrogen overnight. The solvent was removed by evaporation under reduced pressure, and the residue was purified by flash column chromatography using ethyl acetate/n-hexane as eluent to give compound 3b'.

An ethanol suspension (20 mL) of compound 3b' (1 mmol, 326 mg) was heated to 50 °C in the presence of 10 mg of 10% Pd/C, and 0.3 mL of hydrazine monohydrate was added over 30 min to this suspension. The reaction mixture became clear as the reaction proceeded. It was kept at reflux for another 12 h. Upon completion of the reaction, the mixture was filtered over Celite to remove the Pd/C catalyst. The ethanol was removed under reduced pressure. The crude product was purified by flash column chromatography using ethyl acetate/n-hexane as eluent to afford compound 3b''.

Under an ice-water bath, a solution of anilines 3b'' (5 mmol, 1 equiv.) in 5 mL of H₂O in a 25 mL round bottom flask was treated with tetrafluoroboric acid HBF₄·Et₂O (0.82 mL, 1.2 equiv.) by dropwise addition. After that, NaNO₂ (0.52 g, 1.5 equiv.) was dissolved in 3.5 mL of H₂O and dropwise added into the reaction mixture. The resulting mixture was stirred at room temperature for 3 h. Then, the mixture was filtered, and the solid was stepwise washed by ethanol and followed by diethyl ether and further collected as products 3b.
Brownish yellow oil, 75% yield. \( ^1 \text{H NMR} \ (400 \text{ MHz, CDCl}_3) \delta 8.15 \ (d, J = 8.4 \text{ Hz}, 1 \text{H}), 7.92 \ (s, 2 \text{H}), 7.72 \ (s, 2 \text{H}), 7.64 \ (t, J = 7.5 \text{ Hz}, 1 \text{H}), 7.55 - 7.42 \ (m, 9 \text{H}). \) \( ^{13} \text{C NMR} \ (100 \text{ MHz, CDCl}_3) \delta 155.14, 149.31, 149.22, 148.47, 137.71, 135.71, 132.71, 131.66, 130.05, 129.86, 129.61, 129.45, 129.24, 128.65, 127.13, 125.76, 125.74, 124.53, 120.76, 118.41, 115.06. \) HRMS (ESI) \( m/z \) calcd. for \( C_{21}H_{14}N_2O_2 [M + Na]^+ \) 349.0947, found 349.1001.

Yellow powder, 45% yield. \( ^1 \text{H NMR} \ (400 \text{ MHz, CDCl}_3) \delta 8.98 \ (d, J = 8.1 \text{ Hz}, 1 \text{H}), 8.93 \ (d, J = 8.0 \text{ Hz}, 1 \text{H}), 8.45 \ (s, 1 \text{H}), 8.43 - 8.34 \ (m, 2 \text{H}), 8.15 \ (t, J = 7.8 \text{ Hz}, 1 \text{H}), 8.01 \ (t, J = 7.7 \text{ Hz}, 2 \text{H}), 7.81 \ (t, J = 7.6 \text{ Hz}, 1 \text{H}), 7.73 - 7.60 \ (m, 5 \text{H}). \) \( ^{13} \text{C NMR} \ (101 \text{ MHz, DMSO-}d_6) \delta 151.35, 148.20, 146.01, 140.67, 140.51, 137.07, 136.51, 132.59, 131.79, 129.82, 129.53, 129.09, 128.13, 127.97, 126.30, 126.09, 119.14, 118.94, 115.86, 40.15, 39.94, 39.73, 39.52, 39.31, 39.10, 38.89. \) HRMS (ESI) \( m/z \) calcd. for \( C_{21}H_{14}N^+ [M - N_2 - BF_4]^+ \) 280.1121, found 280.1047.
Photophysical Properties of Compounds

The absorption and emission spectra were measured by Cary 8454 UV-Vis Diode Array System and Cary Eclipse Fluorescence Spectrophotometer, respectively, and each quinolizinium compound in CH$_2$Cl$_2$ was diluted in CH$_2$Cl$_2$ prior to measurement. The excitation slit and emission slit for emission measurement were set at 5 nm with scan rate at 120 nm/min and medium PMT voltage. Fluorescent quantum yield of each compound was determined by a comparative method employing fluorescein ($\Phi = 0.95$ in 0.1 N NaOH solution) as standard and calculated with the following equation.$^3$

**Equation 3**

$$
\Phi_{\text{sample}} = \Phi_{\text{standard}} \times \left( \frac{\text{Grad}_{\text{sample}}}{\text{Grad}_{\text{standard}}} \right) \times \left( \frac{n_{\text{sample}}}{n_{\text{standard}}} \right)^2
$$

Where $\Phi$ is the fluorescence quantum yield, Grad the gradient from the plot of integrated fluorescence intensity vs absorbance, and $\eta$ is the refractive index of the solvent.

**Table S3.** Photophysical properties of compounds 1a-1h.$^a$

| Compound | $\lambda_{\text{ex}}$ (nm) | $\lambda_{\text{em}}$ (nm) | Stokes Shift (cm$^{-1}$) | Quantum Yield ($\Phi_F$)$^b$ | Molar Absorptivity ($\varepsilon$) (M$^{-1}$cm$^{-1}$) |
|----------|-----------------|-----------------|-----------------|-----------------|-----------------|
| 1a       | 422             | 482             | 2950            | 0.22            | 10200           |
| 1b       | 435             | 512             | 3457            | 0.20            | 9900            |
| 1c       | 412             | 478             | 3351            | 0.11            | 15700           |
| 1d       | 430             | 555             | 5238            | 0.10            | 6900            |
| 1e       | 445             | 550             | 4290            | 0.22            | 7400            |
| 1f       | 425             | 517             | 4187            | 0.12            | 10200           |
| 1g       | 440             | 550             | 4545            | 0.05            | 5300            |
| 1h       | 405             | 498             | 4611            | 0.21            | 9200            |

$^a$Absorption and emission properties were measured in CH$_2$Cl$_2$ at concentration of µM level. $^b$Quantum yields were measured using coumarin 153 ($\Phi_F = 0.54$ in EtOH) as a standard.
**Procedure of Peptide Modification**

A mixture of 10 µL of cysteine-containing peptides (1 mM in H2O), 10 µL of quinoliziniums 1a–h (1 mM in DMSO) and 80 µL of 50 mM pH 7.4 PBS buffer was treated in a 1.5 -mL Eppendorf tube at 25 °C for 6 h. The modified product was characterized by LC-MS and LC-MS/MS analysis.

**Procedure of Protein Modification**

A mixture of 10 µL of proteins (1 mM in 50 mM pH 7.4 PBS buffer), 5 µL of compound 1a, 1b, 1d, 1e or 1h (4 mM in DMSO) and 85 µL of 50 mM pH 7.4 PBS buffer was treated in a 1.5 -mL Eppendorf tube at 25 °C for 16 h. The modified proteins were purified by Bio-Rad Bio-Spin® 6 column prior to SDS-PAGE, LC-MS (and LC-MS/MS) analysis and trypsin digestion. For the BCArg mutant, 20 mM Tris-HCl buffer pH 7.4 was used instead of 50 mM pH 7.4 PBS buffer.

As shown in Figures S62 and S73, the spectra depict several peaks that are assigned to the commercially available BSA (66433 Da) and HSA (66441 Da), and to the corresponding post-translational modification (PTMs) products, which are attributed to the cysteinylation of Cys34 (66553 Da and 66560 Da, respectively) and non-enzymatic glycation (66723 Da) of HSA.4

**Procedure for SDS-PAGE Analysis**

Protein conjugates (10 µL) were mixed with 2X loading buffer (10 µL) in a 0.5 mL Eppendorf tube and then boiled at 100 °C water bath for 5 min. Samples were analyzed by SDS-PAGE by loading a sample of the boiled solution (10 µL) in each lane of a 15% SDS-PAGE gel and running in a Mini-PROTEAN Tetra Cell (Bio-Rad, USA) at 150 V at room temperature until the front of the dye reached the bottom of the gel. After SDS-PAGE separation, the protein conjugates were visualized at UV 472 nm with Azure C600 Gel Imaging System and finally stained with Coomassie blue.

**Procedure for Trypsin Digestion**

A ratio of 1:50 (w/w) and 1:100 of trypsin (V5280, Promega) to BSA (or HSA) was used for the trypsin digestion of protein conjugates. The reaction mixture was incubated at 37 °C for 24 h and the trypsin-digested mixture was quenched by adding TFA or formic acid to a final concentration of 1% for LC-MS/MS analysis.
In some cases, BCArg mutant did not generate useful peptide sequences after trypsin digestion. Thus, chymotrypsin was required to promote protein cleavage. A ratio of 1:10:25 (w/w/w) and 1:10:50 of trypsin (V5280, Promega), chymotrypsin (V1062, Promega) and BCArg mutant was used for the trypsin digestion of protein conjugates. The reaction mixture was incubated at 37 °C for 24 h and the trypsin-digested mixture was quenched by adding formic acid to a final concentration of 1% for LC-MS/MS analysis.

**Procedure for Site-Directed Mutagenesis of BCArg**

A Cys161 was mutated on Ser161 of BCArg mutant following the procedures as shown below.

**Cloning**

The BCArg mutant plasmid was constructed following the procedures depicted in the patent.5

**Protein Expression and Purification**

DNA plasmid pET3a/BCArg mutant was transformed into competent *E.coli* BL21 (DE3) and the cells were incubated in a Lysogeny broth (LB) plate containing 100 μg/ml ampicillin at 37 °C overnight. Glycerol stocks were prepared with 18% glycerol and stored at -80 °C. BCArg mutant proteins were expressed in pET3a plasmid containing strong T7 promoter by 0.06% lactose induction at 30 °C for 18 h. Cells were collected by centrifugation and the cell pellet was lysed by an ultrasonic homogenizer (QSonica sonicators) in resuspension buffer (1 mM MnCl2, 20 mM Tris buffer, pH 7.4). The crude cell lysates were centrifuged at 16,000 rpm for 2 hours at 4 °C. The clarified supernatant was incubated with 10 mM MnCl2 at 74 °C for 15 min and any white precipitates formed were removed by centrifugation. Proteins were buffer exchanged into binding buffer (20 mM Tris buffer, pH 7.0) and then applied to HiTrap Q HP (GE Healthcare) column. The target proteins bound on the column were eluted by 30% step elution buffer (1 M NaCl/20 mM Tris buffer, pH 7.0). Proteins were buffer exchanged to 20 mM Tris buffer, pH 7.0 and stored in 4 °C.
Figure S7. Chromatogram of BCArg mutant purification by Q column. The target protein was collected by 30% elution buffer and bacterial genomic DNA was removed in the flow-through and 100% elution.

Figure S8. SDS-PAGE analysis of BCArg mutant. Lane 1, protein marker; Lane 2, BCArg mutant crude total protein; Lane 3, BCArg mutant supernatant total protein; Lane 4, 74 °C heat treatment; Lane 5, flow-through from Q column; Lane 6, 30% elution from Q column; Lane 7, 100% from Q column.”
Mutated BCArg Peptide Sequence
MKPISIIGVP MDLGQTRRG GPDMGSPAMRYA GVIERLERLH YDIEDLGDIP
IGKAERLHEQ GDSRLRNLKA VAEANEKLAA AVDQVVQRGR FPLVLGGDHS
IAIGTLAGVA KHYERLGVIV YDAHGDVNTA ETSPSGNIHG MPLAASLGFG
HPALTQIGGY CPKIKPEHVV LIGVRSLDLEG EKKFIREKGI KIYTMHEVDR
LGMTTRVMEET IAYLKERTDG VHLSDLDDLGL DPSDGPGVT PVIGGLTYRE
SHLAMEMLAE AQIITSAEFV EVNPILDERN KTASVAVALM GSLFGEKLM

Enzyme Activity
This assay was used to study the amount of urea produced by BCArg mutant. 200 µL of 20 mM L-Arg solutions were incubated at 37 °C. Reactions were started by adding 5 µL of 20 mM BCArg mutant for 30 seconds and stopped by 15 µL 80% trichloroacetic acid. A colouring reagent was prepared by 1 volume of a mixture of 80 mM diacetyl monoxime and 2.0 mM thiosemicarbazide and 3 volumes of a mixture of 3 M H₃PO₄, 6 M H₂SO₄, 2 mM FeCl₃. 800 µL of the colouring reagent were added to each solution and incubated at 100 °C for 10 min. Absorbance at 530 nm (A530 nm) was evaluated by UV-Vis spectroscopy. The specific activity of BCArg mutant is defined as the micromoles of urea produced per minute under given conditions per mg proteins at 37 °C, pH 7.4 in the phosphate-buffered saline buffer.

Inhibition of in vitro Cancer Cell Proliferation
LoVo cancer cell line (CCL-229™, American Type Culture Collection) was grown in Roswell Park Memorial Institute 1640 Medium (Thermo Fisher Scientific) at 37°C. Cancer Cells were seeded about 3000 cells per well in 96-well plates. The started concentration of BCArg mutant was diluted in 2-fold serial dilution and the plates were incubated for 3 days. Quantitative cell proliferation assays were determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide reagent according to the manufacturer’s instructions. Three independent experiments were performed in triplicate.
$^1$H NMR of Compound 1a

$^{13}$C NMR of Compound 1a
$^1$H NMR of Compound 1b

$^{13}$C NMR of Compound 1b
$^1$H NMR of Compound 1c

$^{13}$C NMR of Compound 1c
$^1$H NMR of Compound 1d

$^{13}$C NMR of Compound 1d
$^1$H NMR of Compound 1e

$^{13}$C NMR of Compound 1e
$^1$H NMR of Compound 1f

$^{13}$C NMR of Compound 1f
$^1$H NMR of Compound 1g

$^{13}$C NMR of Compound 1g
$^{19}\text{F NMR of Compound 1g}$
$^1$H NMR of Compound 1h

$^{13}$C NMR of Compound 1h
$^1$H NMR of Compound 2a

$^{13}$C NMR of Compound 2a
$^1$H NMR of Compound 2b

$^{13}$C NMR of Compound 2b
$^1$H NMR of Compound 3b’
Additional peaks arise due to trace impurities with silicone-grease from the reaction and purification method.

$^{13}$C NMR of Compound 3b’
$^1$H NMR of Compound 3b

$^{13}$C NMR of Compound 3b
Figure S9. Deconvoluted mass spectrum of 1a-modified STSSCNLSK (m/z 1442.60).

Figure S10. MS/MS spectrum and extracted ion chromatogram (Inset) of 1a-modified STSSSCNLSK (ESI source, triply charged ion of m/z 481.88).
Figure S11. Deconvoluted mass spectrum of 1b-modified STSSCNLSK (m/z 1518.66).

Figure S12. MS/MS spectrum and extracted ion chromatogram (Inset) of 1b-modified STSSSCNLSK (ESI source, triply charged ion of m/z 506.90).
Figure S13. Deconvoluted mass spectrum of 1c-modified STSSCNLSK (m/z 1472.62).

Figure S14. MS/MS spectrum and extracted ion chromatogram (Inset) of 1c-modified STSSSCNLSK (ESI source, triply charged ion of m/z 491.55).
Figure S15. Deconvoluted mass spectrum of 1d-modified STSSCNLSK (m/z 1457.62).

Figure S16. MS/MS spectrum and extracted ion chromatogram (Inset) of 1d-modified STSSSCNLSK (ESI source, triply charged ion of m/z 486.88).
Figure S17. Deconvoluted mass spectrum of 1e-modified STSSCNLSK (m/z 1533.66).

Figure S18. MS/MS spectrum and extracted ion chromatogram (Inset) of 1e-modified STSSSCNLSK (ESI source, triply charged ion of m/z 512.22).
Figure S19. Deconvoluted mass spectrum of 1f-modified STSSSCNLSK (m/z 1487.64).

Figure S20. MS/MS spectrum and extracted ion chromatogram (Inset) of 1f-modified STSSSCNLSK (ESI source, triply charged ion of m/z 496.88).
Figure S21. Deconvoluted mass spectrum of 1g-modified STSSSCNLSK (m/z 1525.61).

Figure S22. MS/MS spectrum and extracted ion chromatogram (Inset) of 1g-modified STSSSCNLSK (ESI source, triply charged ion of m/z 509.54).
Figure S23. Deconvoluted mass spectrum of 1h-modified STSSCNLSK (m/z 1457.62).

Figure S24. MS/MS spectrum and extracted ion chromatogram (Inset) of 1h-modified STSSSCNLSK (ESI source, triply charged ion of m/z 486.88).
Figure S25. Deconvoluted mass spectrum of 1a-modified AYEMWCFHQR (m/z 1799.74).

Figure S26. MS/MS spectrum and extracted ion chromatogram (Inset) of 1a-modified AYEMWCFHQR (ESI source, triply charged ion of m/z 600.92).
Figure S27. Deconvoluted mass spectrum of 1b-modified AYEMWCFHQR (m/z 1875.77).

Figure S28. MS/MS spectrum and extracted ion chromatogram (Inset) of 1b-modified AYEMWCFHQR (ESI source, triply charged ion of m/z 626.26).
Figure S29. Deconvoluted mass spectrum of 1e-modified AYEMWCFHQR (m/z 1829.75).

Figure S30. MS/MS spectrum and extracted ion chromatogram (Inset) of 1e-modified AYEMWCFHQR (ESI source, triply charged ion of m/z 610.92).
Figure S31. Deconvoluted mass spectrum of 1d-modified AYEMWCFHQR (m/z 1814.74).

Figure S32. MS/MS spectrum and extracted ion chromatogram (Inset) of 1d-modified AYEMWCFHQR (ESI source, triply charged ion of m/z 605.92).
Figure S33. Deconvoluted mass spectrum of 1e-modified AYEMWCFHQR (m/z 1890.78).

Figure S34. MS/MS spectrum and extracted ion chromatogram (Inset) of 1e-modified AYEMWCFHQR (ESI source, triply charged ion of m/z 631.26).
Figure S35. Deconvoluted mass spectrum of 1f-modified AYEMWCFHQR (m/z 1844.75).

Figure S36. MS/MS spectrum and extracted ion chromatogram (Inset) of 1f-modified AYEMWCFHQR (ESI source, triply charged ion of m/z 615.92).
**Figure S37.** Deconvoluted mass spectrum of 1g-modified AYEMWCFHQR ($m/z$ 1844.75).

**Figure S38.** MS/MS spectrum and extracted ion chromatogram (Inset) of 1g-modified AYEMWCFHQR (ESI source, triply charged ion of $m/z$ 628.58).
Figure S39. Deconvoluted mass spectrum of 1h-modified AYEMWCFHQR (m/z 1814.74).

Figure S40. MS/MS spectrum and extracted ion chromatogram (Inset) of 1h-modified AYEMWCFHQR (ESI source, triply charged ion of m/z 605.92).
Figure S41. Deconvoluted mass spectrum of 1a-modified AYEMWCFHQK (m/z 1771.71).

Figure S42. MS/MS spectrum and extracted ion chromatogram (Inset) of 1a-modified AYEMWCFHQK (ESI source, triply charged ion of m/z 591.58).
**Figure S43.** Deconvoluted mass spectrum of 1d-modified AYEMWCFHQK (m/z 1786.71).

**Figure S44.** MS/MS spectrum and extracted ion chromatogram (Inset) of 1d-modified AYEMWCFHQK (ESI source, triply charged ion of m/z 596.24).
Figure S45. Deconvoluted mass spectrum of 1h-modified AYEMWCFHQK (m/z 1786.71).

Figure S46. MS/MS spectrum and extracted ion chromatogram (Inset) of 1h-modified AYEMWCFHQK (ESI source, triply charged ion of m/z 596.58).
Figure S47. Deconvoluted mass spectrum of 1a-modified CSKFR (m/z 1069.48).

Figure S48. MS/MS spectrum and the extracted ion chromatogram (Inset) of 1a-modified CSKFR (ESI source, triply charged ion of m/z 357.65).
Figure S49. Deconvoluted mass spectrum of 1d-modified CSKFR (m/z 1084.49).

Figure S50. MS/MS spectrum and extracted ion chromatogram (Inset) of 1d-modified CSKFR (ESI source, triply charged ion of m/z 362.17).
**Figure S51.** Deconvoluted mass spectrum of 1h-modified CSKFR (m/z 1084.49).

**Figure S52.** MS/MS spectrum and extracted ion chromatogram (Inset) of 1h-modified CSKFR (ESI source, triply charged ion of m/z 362.16).
Figure S53. Deconvoluted mass spectrum of 1a-modified KSTFC (m/z 1014.42).

Figure S54. MS/MS spectrum and extracted ion chromatogram (Inset) of 1a-modified KSTFC (ESI source, doubly charged ion of m/z 508.14).
Figure S55. Deconvoluted mass spectrum of 1d-modified KSTFC (m/z 1029.43).

Figure S56. MS/MS spectrum of 1d-modified KSTFC (ESI source, doubly charged ion of m/z 515.63).
Figure S57. Deconvoluted mass spectrum of 1h-modified KSTFC (m/z 1029.43).

Figure S58. MS/MS spectrum and extracted ion chromatogram (Inset) of 1h-modified KSTFC (ESI source, doubly charged ion of m/z 515.63).
Figure S59. Deconvoluted mass spectrum of 1a-modified ASCGTN ($m/z$ 981.35).

Figure S60. MS/MS spectrum and extracted ion chromatogram (Inset) of 1a-modified ASCGTN (ESI source, doubly charged ion of $m/z$ 491.60).
Figure S61. Deconvoluted mass spectrum of 1d-modified ASCGTN (m/z 996.37).

Figure S62. MS/MS spectrum and extracted ion chromatogram (Inset) of 1d-modified ASCGTN (ESI source, doubly charged ion of m/z 499.11).
Figure S63. Deconvoluted mass spectrum of 1h-modified ASCGTN ($m/z$ 996.37).

Figure S64. MS/MS spectrum and extracted ion chromatogram (Inset) of 1h-modified ASCGTN (ESI source, doubly charged ion of $m/z$ 499.11).
Figure S65. Deconvolution mass spectrum and extracted ion chromatogram (Inset) of native BSA (PDB: 4F5S) (ESI source, the charged ion of \( m/z \) 1385.00).

Figure S66. Deconvolution spectrum and extracted ion chromatogram (Inset) of 1a-modified BSA (1 equiv. of 1a used) in 50 mM PBS (pH 7.4)/DMSO (95:5) (ESI source, the charged ion of \( m/z \) 1393.94).
Figure S67. Deconvolution mass spectrum and extracted ion chromatogram (Inset) of 1a-modified BSA (2 equiv. of 1a used) in 50 mM PBS (pH 7.4)/DMSO (95:5) (ESI source, the charged ion of m/z 1393.95).

Figure S68. Deconvolution mass spectrum and extracted ion chromatogram (Inset) of 1a-modified BSA (2 equiv. of 1a used) in 50 mM Tris-HCl (pH 7.4)/DMSO (95:5) (ESI source, the charged ion of m/z 1393.95).
Figure S69. Deconvolution spectrum and extracted ion chromatogram (Inset) of 1b-modified BSA (2 equiv. of 1b used) in 50 mM PBS (pH 7.4)/DMSO (95:5) (ESI source, the charged ion of m/z 1395.53).

Figure S70. Deconvolution spectrum and extracted ion chromatogram (Inset) of 1d-modified BSA (2 equiv. of 1d used) in 50 mM PBS (pH 7.4)/DMSO (95:5) (ESI source, the charged ion of m/z 1394.24).
**Figure S71.** Deconvolution spectrum and extracted ion chromatogram (Inset) of 1e-modified BSA (2 equiv. of 1e used) in 50 mM PBS (pH 7.4)/DMSO (95:5) (ESI source, the charged ion of m/z 1394.21).

**Figure S72.** Deconvolution spectrum and extracted ion chromatogram (Inset) of 1h-modified BSA (2 equiv. of 1h used) in 50 mM PBS (pH 7.4)/DMSO (95:5) (ESI source, the charged ion of m/z 1394.25).
Figure S73. MS/MS spectrum of 1a-modified GLVLIASQYLQQCPFDEHK with quarterly charged ion of m/z 955.7988 after trypsin digestion of 1a-modified BSA (2 equiv. of 1a used) in 50 mM PBS (pH 7.4)/DMSO (95:5).
Figure S74. MS/MS spectrum of 1d-modified GLVLIAFSQYLQQCPFDEHVK with (a) quadruply charged ion, \( m/z \) 720.62 and (b) triply charged ion, \( m/z \) 960.48 after trypsin digestion of 1d-modified BSA (2 equiv. of 1d used) in 50 mM PBS (pH 7.4)/DMSO (95:5).
Figure S75. MS/MS spectrum of 1h-modified GLVLIASFQYLQQCPFDEHKV with (a) triply charged ion of m/z 960.48 and (b) quarterly charged ion of m/z 720.61 after trypsin digestion of 1h-modified BSA (2 equiv. of 1h used) in 50 mM PBS (pH 7.4)/DMSO (95:5).
Figure S76. Deconvolution spectrum and extracted ion chromatogram (Inset) of native HSA (PDB: 1AO6) (ESI source, the charged ion of m/z 1445.34).

Figure S77. Deconvolution spectrum and extracted ion chromatogram (Inset) of 1a-modified HSA (2 equiv. of 1a used) in 50 mM PBS (pH 7.4)/DMSO (95:5) (ESI source, the charged ion of m/z 1454.85).
Figure S78. Deconvolution spectrum and extracted ion chromatogram (Inset) of 1b-modified HSA (2 equiv. of 1b used) in 50 mM PBS (pH 7.4)/DMSO (95:5) (ESI source, the charged ion of m/z 1456.43).

Figure S79. Deconvolution spectrum and extracted ion chromatogram (Inset) of 1d-modified HSA (2 equiv. of 1d used) in 50 mM PBS (pH 7.4)/DMSO (95:5) (ESI source, the charged ion of m/z 1455.02).
Figure S80. Deconvolution spectrum and extracted ion chromatogram (Inset) of 1e-modified HSA (2 equiv. of 1e used) in 50 mM PBS (pH 7.4)/DMSO (95:5) (ESI source, the charged ion of m/z 1456.68).

Figure S81. Deconvolution spectrum and extracted ion chromatogram (Inset) of 1h-modified HSA (2 equiv. of 1h used) in 50 mM PBS (pH 7.4)/DMSO (95:5) (ESI source, the charged ion of m/z 1455.02).
Figure S82. MS/MS spectrum of 1d-modified ALVLIAFAQYLQCPFEDHVK with triply charged ion of m/z 959.82 after trypsin digestion of 1d-modified HSA (2 equiv. of 1d used) in 50 mM PBS (pH 7.4)/DMSO (95:5).
Figure S83. MS/MS spectrum of 1h-modified ALVLIAFAQYLQCPFEDHVK with (a) triply charged ion of m/z 959.82 and (b) quarterly charged ion of m/z 721.12 after trypsin digestion of 1h-modified HSA (2 equiv. of 1hused) in 50 mM PBS (pH 7.4)/DMSO (95:5).
**Figure S84.** Deconvolution spectrum and extracted ion chromatogram (Inset) of the BCArg mutant (ESI source, the charged ion of m/z 984.25).

**Figure S85.** Deconvolution spectrum and extracted ion chromatogram (Inset) of 1a-modified BCArg mutant (1 equiv. of 1a used) in 20 mM Tris-HCl (pH 7.4)/DMSO (95:5) (ESI source, the charged ion of m/z 997.29).
Figure S86. Deconvolution spectrum and extracted ion chromatogram (Inset) of 1a-modified BCArg mutant (2 equiv. of 1a used) in 20 mM Tris·HCl (pH 7.4)/DMSO (95:5) (ESI source, the charged ion of m/z 997.29).

Figure S87. Deconvolution spectrum and extracted ion chromatogram (Inset) of 1b-modified BCArg mutant (2 equiv. of 1b used) in 20 mM Tris·HCl (pH 7.4)/DMSO (95:5) (ESI source, the charged ion of m/z 999.60).
Figure S88. Deconvolution spectrum and extracted ion chromatogram (Inset) of 1d-modified BCArg mutant (2 equiv. of 1d used) in 20 mM Tris·HCl (pH 7.4)/DMSO (95:5) (ESI source, the charged ion of m/z 997.74).

Figure S89. Deconvolution spectrum and extracted ion chromatogram (Inset) of 1e-modified BCArg mutant (2 equiv. of 1e used) in 20 mM Tris·HCl (pH 7.4)/DMSO (95:5) (ESI source, the charged ion of m/z 1000.04).
**Figure S90.** Deconvolution spectrum and extracted ion chromatogram (Inset) of 1h-modified BCArg mutant (2 equiv. of 1h used) in 20 mM Tris·HCl (pH 7.4)/DMSO (95:5) (ESI source, the charged ion of $m/z$ 997.74).
Figure S91. MS/MS spectrum of 1e-modified CPKIKPEHVVLIGVRSLEGEKKF with quadruply charged ion, m/z 812.45 after trypsin digestion of 1e-modified BCArg mutant.
Figure S92. MS/MS spectrum of 1h-modified LGVIWYDAHDVNATAETSPSGNIHGMPLAASLGFHELQALTIGGYCPK with sextuply charged ion, m/z 895.44 after trypsin digestion of 1h-modified BCArg mutant.
UV/Visible Absorption Spectra of Quinolizinium Compounds

Figure S93. Absorption spectrum of compound 1a.

Figure S94. Absorption spectrum of compound 1b.
Figure S95. Absorption spectrum of compound 1c.

Figure S96. Absorption spectrum of compound 1d.
**Figure S97.** Absorption spectrum of compound 1e.

**Figure S98.** Absorption spectrum of compound 1f.
Figure S99. Absorption spectrum of compound 1g.

Figure S100. Absorption spectrum of compound 1h.
Emission spectrum of quinolizinium compounds

Figure S101. Emission spectrum of compound 1a.

Figure S102. Emission spectrum of compound 1b.
Figure S103. Emission spectrum of compound 1c.

Figure S104. Emission spectrum of compound 1d.
Figure S105. Emission spectrum of compound 1e.

Figure S106. Emission spectrum of compound 1f.
**Figure S107.** Emission spectrum of compound 1g.

**Figure S108.** Emission spectrum of compound 1h.
Supplementary References

1. J.-R. Deng, W.-C. Chan, N. Chun-Him Lai, B. Yang, C.-S. Tsang, B. Chi-Bun Ko, S. Lai-Fung Chan and M.-K. Wong, Chem. Sci., 2017, 8, 7537-7544.

2. For selected examples, see (a) L. Purushottam, S. R. Adusumalli, U. Singh, V. B. Unnikrishnan, D. G. Rawale, M. Gujrati, et al. Nat. Commun., 2019, 10, 2539. (b) J. Willwacher, R. Raj, S. Mohammed and B. G. Davis, J. Am. Chem. Soc., 2016, 138, 8678-8681. (c) P. Dai, C. Zhang, M. Welborn, J. J. Shepherd, T. Zhu, T. Van Voorhis, et al. ACS Cent. Sci., 2016, 2, 637-646. (d) Y. A. Lin, J. M. Chalker and B. G. Davis, J. Am. Chem. Soc., 2010, 132, 16805-16811.

3. K. Rurack and M. Spieles, Anal. Chem., 2011, 83, 1232-1242.

4. (a) M. Kleinova, O. Belgacem, K. Pock, A. Rizzi, A. Buchacher and G. Allmaier, Rapid Commun. Mass Spectrom. 2005, 19, 2965–2973; (b) A. Pratesi, D. Cirri, D. Fregona, G. Ferraro, A. Giorgio, A. Merlino and L. Messori, Inorg. Chem., 2019, 58, 10616–10619.

5. Y. C. Leung, W. Lo, Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents, U.S. Patent 8507245B2, Aug 13, 2013.

6. S.-F. Chung, C.-F. Kim, S.-Y. Tam, M.-C. Choi, P.-K. So, K.-Y. Wong, Y.-C. Leung and W.-H. Lo, Appl. Microbiol. Biotechnol., 2020, 104, 3921-3934.